MannKind to Present at Upcoming Conferences

Rhea-AI Summary

MannKind (Nasdaq: MNKD), a company developing inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:

• 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 11:00 a.m. ET
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6 at 7:00 a.m. ET
• H.C. Wainwright 26th Annual Global Investment Conference in New York on September 10 at 9:30 a.m. ET

Live audio webcasts will be available on MannKind's website, with recordings accessible for about 30 days after each conference.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during fireside chats at three upcoming investor conferences:

2024 Wells Fargo Healthcare Conference in Boston
Wednesday, September 4
11:00 a.m. Eastern Time

Morgan Stanley 22^nd Annual Global Healthcare Conference in New York
Friday, September 6
7:00 a.m. Eastern Time

H.C. Wainwright 26^th Annual Global Investment Conference in New York
Tuesday, September 10
9:30 a.m. Eastern Time

Links to access live audio webcasts of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. An archived, recorded version will also be available on the website for approximately 30 days following each conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

MANNKIND is a registered trademark of MannKind Corporation.

FAQ

What investor conferences will MannKind (MNKD) attend in September 2024?

MannKind will attend three investor conferences in September 2024: the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 6, and the H.C. Wainwright Global Investment Conference in New York on September 10.

Who will represent MannKind (MNKD) at the upcoming investor conferences?

MannKind will be represented by Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss at the upcoming investor conferences.

How can investors access MannKind 's (MNKD) presentations at the September 2024 conferences?

Investors can access live audio webcasts of MannKind 's presentations through the company's website at https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will be available for approximately 30 days following each conference.

What is the focus of MannKind 's (MNKD) business?

MannKind focuses on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases.